Comparative Pharmacology
Head-to-head clinical analysis: PRECEF versus ZEVTERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRECEF versus ZEVTERA.
PRECEF vs ZEVTERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftobiprole, the active moiety of ZEVTERA, is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in methicillin-resistant Staphylococcus aureus (MRSA), leading to cell death.
1-2 g IV every 6-8 hours; maximum 12 g/day.
400 mg intravenously every 8 hours
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-8 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 3.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to ~6 hours, requiring dose adjustment.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal <10%.
Approximately 70% of the dose is excreted unchanged in urine, with 20% recovered in feces via biliary elimination. Minor route: <5% as metabolites.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic